智通财经记者 | 袁颖琪 嘉必优（688089.SH）发布了2025年上半年业绩预告，预计实现营业收入3.07亿元，同比增长17.59%。净利润达1.07亿 元，同比增长57.6%，创下单季新高。 然而，这份高增长背后暗藏隐忧。不难发现，嘉必优的营收增速远低于利润增幅。公司解释，主因ARA产品单价出现 下降。 但这只是表面原因。嘉必优有94%收入依赖婴幼儿奶粉客户，与国内新生儿数量持续下降形成根本矛盾；燕窝酸、 HMOs等储备产品产业化缓慢，技术转化效率拖累新增长点培育。此外，公司高溢价收购的欧易生物，给嘉必优带来了 6.82亿商誉，埋下商誉风险。 嘉必优的合成生物学进击之路，正面临技术转化、客户依赖与资本豪赌的三大生存命题。 技术转化：实验室到货架的距离有多远？ 嘉必优通过改造微生物菌种，使其在发酵罐中高效生产高附加值营养素，其商业模式类似"细胞工厂"。 图片来源：智通财 经研究部制图 根据2024年年报，嘉必优的主要产品包括ARA（花生四烯酸）和藻油DHA。ARA作为婴幼儿配方奶粉必需成分，作用 是促进婴幼儿大脑发育，占公司2024年总收入的70.25%。 藻类DHA替代传统鱼油来源的DHA（二十二碳六烯 ...

易德伟，本科学历。1987年7月至1991年12月，任华中师范大学科研处副科长、代理科长；1991年12月至1993年2月,任职于国家教育委员会(现国家教育部)社 会科学司规划处；1993年10月至1999年12月，任北京纳英文化传播公司董事长；1999年12月至今，任武汉烯王生物工程有限公司董事长；2009年11月至今， 任武汉烯王投资有限公司董事长；2004年9月至2015年12月，历任嘉必优生物工程(武汉)有限公司董事长、总经理；2015年12月至今，任嘉必优董事长兼总 经理。2023年9月起至今，兼任长江产业科技创新专家咨询委员会专家委员。 东方财富数据显示，2020年至2024年，易德伟的薪酬分别为108.8万元、115.7万元、118.0万元、109.1万元、116.1万元。 杜斌，本科学历。1987年7月至1999年12月，历任华中师范大学学生管理科科长、历史文化学院副书记；1999年12月至2004年8月，任武汉烯王生物工程有限 公司人力资源部经理、董事会秘书；2004年9月至今，任武汉烯王生物工程有限公司董事；2004年9月至2015年12月，历任嘉必优生物工程(武汉)有限公司副 总经理、执 ...

长江商报消息 ●长江商报记者 徐靓丽 嘉必优（688089.SH）日前发布2025上半年度业绩预报，公司预计实现营业收入约3.07亿元，较上年同 期增长约17.59%；预计实现归母净利润约1.07亿元，较2024年同期增长57.61%。同时，公司产品燕窝酸 正式进入化妆品原料目录，在化妆品和食品领域双双获得"准入"。 预计营收净利双增长 2021年开始，在《化妆品监督管理条例》与《食品安全法》的双重实施下，中国对化妆品与食品原料的 管理进入了"强监管"时代。新规要求所有未收录原料必须完成备案及3年安全监测期，这一政策直接打 破行业长期依赖进口原料的僵局。新规实施5个月后，中科光谷（嘉必优子公司）提交的燕窝酸备案申 请获批，成为新规后首个完成备案的化妆品原料。 实际上，燕窝酸2017年就已获原国家卫计委批准为新食品原料，每日推荐摄入量≤500毫克。2022年， 中科光谷研发的燕窝酸被国家卫健委认定为与已批准公告的N-乙酰神经氨酸新食品原料具有实质等同 性。这也意味着燕窝酸在化妆品和食品领域双双获得"准入"。 6月24日，国家药监局公告称，"N-乙酰神经氨酸"（燕窝酸）已通过3年安全监测期，并作为首批新原料 被纳 ...

Reinstatement - Changhong High-Tech plans to acquire 100% equity of Guangxi Changke through issuing shares, convertible bonds, and cash payment, focusing on the R&D of special synthetic resins, with stock reinstatement [1] - Jichuan Pharmaceutical disclosed the results of the acquisition offer by Cao Fei, leading to stock reinstatement [2] - *ST Yazhen completed the verification work, resulting in stock reinstatement [3] Capital Increase and Mergers - Chiplink Integration intends to purchase 72.33% equity of Chiplink Yuezhou for 5.897 billion yuan [4] - Dongwu Securities plans to raise no more than 6 billion yuan through a private placement for subsidiary capital increase, IT and compliance investments, wealth management, bond investments, debt repayment, and working capital [4] - Weiguang Biological aims to raise no more than 1.5 billion yuan for its smart industrial base project and to supplement working capital [5] - Zhengyu Industrial plans to raise no more than 450 million yuan for the second phase of Zhengyu Intelligent Manufacturing Park and to supplement working capital [6] Equity Transfer - Liangpinpuzi's Ningbo Hanyi plans to transfer 5.10% of its shares to Wanggu Chuangtou at a price of 12.42 yuan per share, totaling 254 million yuan [7] - Dongfang Caifu's shareholder Shen Yougen intends to transfer 1% of the company's shares, with a familial relationship to the actual controller [8] External Investment and Daily Operations - Shangshi Development's wholly-owned subsidiary Quanzhou Shangshi plans to transfer its holdings in the Quanzhou Fengze District Shangshi Haishang project to Quanzhou Kaiyuan's wholly-owned subsidiaries for approximately 2.05 billion yuan [9] - Rik Chemical signed a strategic cooperation framework agreement with Shandong Dongming Petrochemical Group for collaboration in specialized polyethylene powder supply, industry ecosystem building, and new product development [10] - Huadong Pharmaceutical's wholly-owned subsidiary received approval for clinical trials of the injectable HDM2012 drug [11] - Dongrui Co. obtained additional export quotas for live pigs to Hong Kong and Macau for 2025 [12] - Kuaibingtong's largest shareholder Yang Jianxin successfully auctioned 8 million shares [13] - Pulite's subsidiary introduced strategic investor Guoyan No. 1 through capital increase and expansion [14] - Bohui Co. plans to purchase servers, data center facilities, and related services through its wholly-owned subsidiary Wuxi Jizhi Liquid Cooling Technology, with an estimated total amount not exceeding 900 million yuan [15] - Lianhuan Pharmaceutical received approval for clinical trials of the drug Riluzole [16] Performance Changes - Jiabiyou expects a net profit of approximately 107 million yuan for the first half of the year, a year-on-year increase of 57.61%, driven by increased sales of core products ARA and algae oil DHA [17] - Sanhuan Group anticipates a net profit of 1.128 billion to 1.333 billion yuan for the first half of the year, a year-on-year increase of 10% to 30%, with significant sales growth in MLCC products [18] - Shentong Technology reported a net profit of 64.278 million yuan for the first half of the year, a year-on-year increase of 111.09% [19] - Nanjing Gaoke's contract sales reached 820 million yuan for the first half of the year, a year-on-year increase of 824.68% [20]

嘉必优公告，2025年半年度实现营业收入约3.07亿元，较上年同期增长17.59%；归属于母公司所有者的 净利润约1.07亿元，较上年同期增长57.61%；归属于母公司所有者的扣除非经常性损益的净利润约9300 万元，较上年同期增长75.45%。报告期内公司营业收入增加主要系核心产品ARA和藻油DHA销量增加 所致；利润增加主要系营业收入增加，同时公司生产效率提升，叠加产品结构和客户结构优化，提升了 公司的盈利能力。 ...

Core Viewpoint - The company, Jiabiyou Biotechnology (Wuhan) Co., Ltd., is undergoing a significant asset restructuring by acquiring a 63.2134% stake in Shanghai Ouyi Biomedical Technology Co., Ltd. through a combination of issuing shares and cash payment, with the total transaction value estimated at approximately 83,062.37 million RMB [1][2]. Group 1: Company Overview - Jiabiyou Biotechnology was established on September 22, 2004, with a registered capital of 120 million RMB, located in Wuhan, China [1]. - The company operates in the food manufacturing industry, focusing on the research, production, and sales of polyunsaturated fatty acids such as ARA and DHA, as well as natural β-carotene, primarily for infant formula, health foods, and dietary supplements [1][2]. Group 2: Major Asset Restructuring - The restructuring involves acquiring a 63.2134% equity stake in Shanghai Ouyi Biomedical Technology Co., Ltd., with an assessed value of 131,600 million RMB for the entire equity and 83,188.80 million RMB for the stake being acquired [1][2]. - The share issuance price is set at 19.29 RMB per share, which is not less than 80% of the average stock price over the previous 20 trading days [1][2]. Group 3: Financial Reporting Basis - The pro forma financial statements are prepared under the assumption that the restructuring was completed on January 1, 2023, and are based on the new equity structure post-restructuring [2][3]. - The financial statements do not include cash flow statements or changes in equity, focusing solely on pro forma consolidated financial information [4][5]. Group 4: Accounting Policies - The company follows the Chinese Accounting Standards, with a fiscal year from January 1 to December 31, and uses RMB as its functional currency [6][7]. - The company employs a weighted average method for inventory valuation and recognizes impairment losses for inventory when the net realizable value is lower than the cost [12][13]. Group 5: Financial Instruments - Financial assets are classified based on the business model and cash flow characteristics, with categories including those measured at amortized cost and those measured at fair value [14][15]. - The company assesses expected credit losses for financial assets measured at amortized cost, applying a three-stage model based on credit risk changes [19][20]. Group 6: Long-term Investments and Fixed Assets - Long-term equity investments are accounted for using the cost method for controlled entities and the equity method for joint ventures and associates [24]. - Fixed assets are depreciated using the straight-line method, with specific depreciation rates and useful lives defined for different asset categories [26][27].

Market Outlook - The market for health-conscious products is expected to grow significantly due to rising income levels and changing consumer preferences towards sugar-free and nutritious options [2] - The aging population presents a substantial opportunity in the silver economy, with increasing demand for health improvement products [2] - National policies are anticipated to further boost the market for natural sweeteners and functional health foods such as prebiotics and dietary fibers [2] Revenue Projections - The company aims for a net profit of no less than 170 million RMB in 2025 as part of its stock incentive plan [6] - The company expects stable growth in its three core products: prebiotics, dietary fibers, and sugar-reducing sweeteners [4] Production Capacity - The company has initiated a project to expand its production capacity of allulose to 20,000 tons annually, with an expected total capacity of approximately 30,000 tons by 2026 [3] - The company has completed the construction of a 2,500-ton annual production line for HMOs (human milk oligosaccharides) and is currently in the trial production phase [6] Impact of Raw Material Prices - The company is closely monitoring corn prices and employing strategies to balance procurement costs and market uncertainties [3] Export and Market Expansion - The company plans to establish a sales subsidiary in the U.S. and enhance customer service to increase market share [7] - The company’s export business to the U.S. is expected to benefit from reduced tariffs, which will facilitate exports [4] Industry Trends - The overall industry is benefiting from the growing health consciousness among consumers and the aging population, which is driving demand for health-related products [11] - The company’s market share for erythritol in the EU has increased to 50%, with a significant revenue growth of approximately 123% year-on-year in Q1 2025 [5] Stock Performance and Investor Relations - The company is actively engaging in investor relations to improve market perception and stock performance, including hosting analyst meetings and enhancing information disclosure [10] - The company acknowledges that stock price is influenced by various factors, including company earnings and market conditions [12]

Core Viewpoint - The company is focusing on high-value core products such as prebiotics, dietary fibers, and sugar-reducing sweeteners, which are expected to drive future growth and profitability [2][3][4]. Product Focus - The company's core products include prebiotics (oligomaltose, fructooligosaccharides, galactooligosaccharides), dietary fibers (polydextrose, resistant dextrin), and sugar-reducing sweeteners (erythritol, crystalline fructose, allulose) [2]. Gross Margin Improvement - The gross margin for the company's core products increased from 9.74% in 2023 to 15.84% in 2024, driven by optimized product structure, reduced consumption, and lower procurement costs [3][4]. - The gross margins for individual core products are as follows: prebiotics increased from 19.34% to 24.60%, dietary fibers from 12.64% to 18.12%, and sugar-reducing sweeteners from 1.26% to 9.09% [4]. Production Strategy - The company is implementing a "small, refined, and flexible" production model to cater to differentiated market demands, focusing on high-value, small-batch orders [6]. - The flexible production plan aims to enhance responsiveness to market needs and build competitive advantages through customized products [6]. New Product Development - The company is expanding its product line with high-value products such as DHA algae oil, lactulose, and HMOs, with production capacity already established for these new products [8]. - Strategic partnerships have been formed to ensure sales of new products, with ongoing projects in trial production stages [8]. Market Impact of Tariffs - Following the EU's imposition of anti-dumping duties on erythritol, the company has capitalized on being the lowest taxed entity, resulting in a 123% year-on-year increase in erythritol sales revenue in Q1 2025 [8]. Capacity Expansion - The company has been a pioneer in the domestic allulose market, with a production capacity exceeding 5,000 tons set to be expanded to 20,000 tons in the future [9]. Financial Performance - In Q1 2025, the company reported a revenue of 685 million yuan, a 24.23% increase year-on-year, and a net profit of 50.36 million yuan, up 117.35% year-on-year [10].

Group 1: Company Overview - The company specializes in the research, production, and sales of functional ingredients such as prebiotics, dietary fibers, and sugar-reducing sweeteners, aiming to be a global leader in functional ingredients and health food innovation [2] - The company has established a full industrial chain manufacturing system, meeting diverse procurement needs of downstream customers [2] Group 2: Financial Performance - In 2024, the company achieved a net profit of 111.16 million CNY, a year-on-year increase of 105.97%, and a net profit of 123.90 million CNY after deducting non-recurring gains and losses, up 254.56% [2] - Total revenue for 2024 was 2.40 billion CNY, a decrease of 4.84% due to the intentional reduction of low-value feed and by-product businesses, while core product revenue and profit saw significant growth [2] Group 3: Product Performance - Revenue from prebiotics in 2024 reached 334.99 million CNY, up 16.02%, with a sales volume of 36,000 tons, a 23.74% increase [2] - Dietary fibers generated 238.40 million CNY in revenue, a 14.52% increase, with a sales volume of 21,400 tons, up 14.39% [2] - Sugar-reducing sweeteners achieved 516.10 million CNY in revenue, a 29.73% increase, with a sales volume of 50,000 tons, up 41.66% [2] Group 4: Margin Improvement - The gross margin for core products improved from 9.74% in 2023 to 15.84% in 2024, with prebiotics' margin rising to 24.60%, dietary fibers to 18.12%, and sugar-reducing sweeteners to 9.09% [6] - Key reasons for margin improvement include optimized product structure, reduced production costs, and lower procurement costs [5] Group 5: Strategic Initiatives - The company is focusing on a "small, refined, and flexible" production model, targeting small-batch, high-value, and differentiated orders [8] - New product developments include DHA algae oil, lactulose, and HMOs, with production capacity expansions underway [9] Group 6: Market Impact - The EU's anti-dumping tax on erythritol, ranging from 34.4% to 233.3%, has led to a 123% year-on-year increase in sales revenue for the company's erythritol products in Q1 2025 [10] - The company does not anticipate significant impacts from U.S.-China trade tensions, as exports to the U.S. represent a small portion of total revenue [12]

作者：FBIF Foodtalks沙龙将与FBIF2025食品饮料创新论坛同期举办。除了嘉宾分享，这一次，我们选择让真实的 人生故事成为灯塔。FBIF2025特别策划" 破界者说 "沙龙，邀请食品饮料行业 20位 跨代际、跨赛道的 践行者分享他们的从业故事。 他们有人在业务转型中成长，有人从0到1做了海外拓展，有人做过滑翔伞运动员，有人是"创二代"接 班，有人GAP转型归来……每个故事都是一枚棱镜，折射出商业逻辑背后更本质的命题——如何在理想 主义与现实主义之间搭建悬梯？当浪潮退去时，什么是值得坚守的"职业锚点"？我们相信，真正的启发 从不来自完美叙事，而是来自真实困境的碰撞与共鸣。它们或许不足以指明方向，但能让你在暗潮中触 碰到同频共振的心跳。 5月8-10日，上海国家会展中心，Foodtalks沙龙邀你莅临！ 胡亚军 集团副总裁 东鹏饮料 王钟和 创始人 可漾 邹旸博士 党委书记兼董事长 海河乳品公司 Öarmilk吾岛 王炜建 创始人兼CEO 康诺食品乳品集团 &吾岛希腊酸奶 118 用主角主 易子涵 创始人兼CEO 松鲜鲜 夏巍华 总经理 佳乐歌 亚 邢正轩 创始人 野人日记 日 - 烘焙专家 刘洁 ...